Literature DB >> 9870257

Adoptive immunotherapy for Epstein-Barr virus-associated lymphoproliferative disorders complicating marrow allografts.

R J O'Reilly1, T N Small, E Papadopoulos, K Lucas, J Lacerda, L Koulova.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9870257     DOI： 10.1007/BF00838055

Source DB:  PubMed          Journal:  Springer Semin Immunopathol        ISSN： 0344-4325


× No keyword cloud information.
  212 in total

1.  A virus-specific CD4+ cell-mediated cytolytic activity revealed by CD8+ cell elimination regularly develops in uncloned human antiviral cell lines.

Authors:  I Bourgault; A Gomez; E Gomard; F Picard; J P Levy; E Gomrad
Journal:  J Immunol       Date:  1989-01-01       Impact factor: 5.422

2.  A re-examination of the Epstein-Barr virus carrier state in healthy seropositive individuals.

Authors:  Q Y Yao; A B Rickinson; M A Epstein
Journal:  Int J Cancer       Date:  1985-01-15       Impact factor: 7.396

3.  Long-term T-cell-mediated immunity to Epstein-Barr virus in man. I. Complete regression of virus-induced transformation in cultures of seropositive donor leukocytes.

Authors:  D J Moss; A B Rickinson; J H Pope
Journal:  Int J Cancer       Date:  1978-12       Impact factor: 7.396

Review 4.  Risk factors and pathogenesis of posttransplant lymphoproliferative disorders.

Authors:  M Ho
Journal:  Transplant Proc       Date:  1995-10       Impact factor: 1.066

5.  Epstein-Barr virus nuclear antigen 2 specifically induces expression of the B-cell activation antigen CD23.

Authors:  F Wang; C D Gregory; M Rowe; A B Rickinson; D Wang; M Birkenbach; H Kikutani; T Kishimoto; E Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

6.  Characterization of the T cell-mediated cellular cytotoxicity during acute infectious mononucleosis.

Authors:  B E Tomkinson; R Maziarz; J L Sullivan
Journal:  J Immunol       Date:  1989-07-15       Impact factor: 5.422

7.  Epstein-Barr virus latent membrane protein-1 oncogene deletions: correlations with malignancy in Epstein-Barr virus--associated lymphoproliferative disorders and malignant lymphomas.

Authors:  D W Kingma; W B Weiss; E S Jaffe; S Kumar; K Frekko; M Raffeld
Journal:  Blood       Date:  1996-07-01       Impact factor: 22.113

8.  Large clonal expansions of CD8+ T cells in acute infectious mononucleosis.

Authors:  M F Callan; N Steven; P Krausa; J D Wilson; P A Moss; G M Gillespie; J I Bell; A B Rickinson; A J McMichael
Journal:  Nat Med       Date:  1996-08       Impact factor: 53.440

9.  Genetic analysis of immortalizing functions of Epstein-Barr virus in human B lymphocytes.

Authors:  W Hammerschmidt; B Sugden
Journal:  Nature       Date:  1989-08-03       Impact factor: 49.962

10.  Signalling downstream of activated mammalian Notch.

Authors:  S Jarriault; C Brou; F Logeat; E H Schroeter; R Kopan; A Israel
Journal:  Nature       Date:  1995-09-28       Impact factor: 49.962
View more
  5 in total

Review 1.  Immunotherapeutic options for Epstein-Barr virus-associated lymphoproliferative disease following transplantation.

Authors:  Donald R Shaffer; Cliona M Rooney; Stephen Gottschalk
Journal:  Immunotherapy       Date:  2010-09       Impact factor: 4.196

Review 2.  Immune deficits in allogeneic hematopoietic stem cell transplant (HSCT) recipients.

Authors:  Muhammad A Mir; Minoo Battiwalla
Journal:  Mycopathologia       Date:  2009-01-21       Impact factor: 2.574

3.  Antiviral responses following L-leucyl-L-leucine methyl esther (LLME)-treated lymphocyte infusions: graft-versus-infection without graft-versus-host disease.

Authors:  Joanne Filicko-O'Hara; Dolores Grosso; Phyllis R Flomenberg; Thea M Friedman; Janet Brunner; William Drobyski; Andres Ferber; Irina Kakhniashvili; Carolyn Keever-Taylor; Bijoyesh Mookerjee; Julie-An Talano; John I Wagner; Robert Korngold; Neal Flomenberg
Journal:  Biol Blood Marrow Transplant       Date:  2009-09-08       Impact factor: 5.742

4.  Cytolytic CD4(+)-T-cell clones reactive to EBNA1 inhibit Epstein-Barr virus-induced B-cell proliferation.

Authors:  Sarah Nikiforow; Kim Bottomly; George Miller; Christian Münz
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

5.  Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease.

Authors:  Catherine M Bollard; Laura Aguilar; Karin C Straathof; Benedikt Gahn; M Helen Huls; Alexandra Rousseau; John Sixbey; M Victoria Gresik; George Carrum; Melissa Hudson; Dagmar Dilloo; Adrian Gee; Malcolm K Brenner; Cliona M Rooney; Helen E Heslop
Journal:  J Exp Med       Date:  2004-12-20       Impact factor: 14.307
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.